ard-101
·Code: ARD-101
ard-101: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Aardvark Therapeutics, Inc. (AARD) | Phase 3 |
Clinical Trials (1)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome
FDA Decisions
FDA_MeetingFDA alignment on protocol amendment lowering minimum eligible age in Phase 3 HERO trial from 13 to 10 years for treatment of hyperphagia in Prader-Willi Syndrome.(AARD)
Frequently asked questions
Who is developing ard-101?
ard-101 is being developed by Aardvark Therapeutics, Inc..
How many clinical trials involve ard-101?
BioSniper tracks 1 clinical trial involving ard-101.
What is ard-101's latest FDA decision?
The most recent tracked FDA decision for ard-101 is FDA_Meeting for FDA alignment on protocol amendment lowering minimum eligible age in Phase 3 HERO trial from 13 to 10 years for treatment of hyperphagia in Prader-Willi Syndrome., dated October 8, 2025.
Get deeper analysis on ard-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis